| Cat.No. | Name | Information |
|---|---|---|
| M8959 | BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) | BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) is an inhibitor of PD-1/PD-L1 protein/protein interaction with an IC50 of 6 to 100 nM. |
| M6101 | Atezolizumab | Atezolizumab (atezolizumab) is a humanized anti-PD-L1 monoclonal antibody that inhibits PD-L1 signaling with PD-1 and B7-1 and restores tumor-specific T-cell immunity. However, it does not affect the interaction of PD-L2 with PD-1. Atezolizumab reacts with murine PD-L1 (for human and non-humanized mice). |
| M3813 | Avelumab (MSB0010718C) | Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). Avelumab recognizes murine PD-L1 |
| M6100 | Nivolumab | Nivolumab (nabumab) is a fully humanized IgG4 monoclonal antibody against PD-1. It has immune checkpoint inhibitory activity and antitumor activity; MW: 143.597 KD.(for human-derived mice). |
| M5144 | BMS202 | Bms-202 is an effective non-peptide PD-1/PD-L complex inhibitor with IC50 of 18 nM and KD of 8 μM. Bms-202 directly binds to PD-L1 and blocks the human PD-1/PD-L interaction. Bms-202 has antitumor activity. |
| M6102 | Pembrolizumab | Pembrolizumab (pembrolizumab) is a humanized anti-PD-1 monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2. It has immune checkpoint inhibitory activity and antitumor activity. MW: 146.286 KD.(Pembrolizumab does not recognize murine PD-1 protein, humanized mice or mice expressing human PD-1 gene are required). |
| M54548 | Benmelstobart | Benmelstobart is an anti-PD-L1 humanized IgG1ҡ monoclonal antibody that can be used for tumor-related studies. |
| M54428 | Human PD-L1 inhibitor II | Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity. |
| M54299 | Human PD-L1 inhibitor I | Human PD-L1 inhibitor I is a hPD-1 peptide ligand, with a KD of 3.39 μM. |
| M54045 | Human PD-L1 inhibitor IV | Human PD-L1 inhibitor IV, a polypeptide, is a competitive human PD-1 protein inhibitor with a Kd value of 1.38 μM. |
| M52843 | Human PD-L1 inhibitor III | Human PD-L1 inhibitor III is a human PD-L1 inhibitor. |
| M52842 | [D-Leu-4]-OB3 | [D-Leu-4]-OB3 inhibits expressions of pro-inflammatory, proliferative and metastatic genes and PD-L1 expression. |
| M52840 | Human membrane-bound PD-L1 polypeptide | Human membrane-bound PD-L1 polypeptide can be used as an antigen to induce PD-L1 antibody production. |
| M42034 | PD-1/PD-L1-IN-33 | PD-1/PD-L1-IN-33 is a PD-1/PD-L1 inhibitor. |
| M42033 | PD-1/PD-L1-IN-31 | PD-1/PD-L1-IN-31 is a PD-1/PD-L1 inhibitor (IC50=2.2 nM). |
| M42032 | PD1-PDL1-IN 1 TFA | PD1-PDL1-IN 1 TFA is a potent programmed cell death 1 (PD-1) inhibitor. |
| M42031 | PD-L1-IN-2 | PD-L1-IN-2 is a potential tumor immunological agent by inhibiting PD-L1. |
| M42030 | PD-1/PD-L1-IN-32 | PD-1/PD-L1-IN-32 is a potent PD-1/PD-L1 inhibitor (IC50=2.4 nM), with anticancer activity. |
| M42029 | PD-L1-IN-3 | PD-L1-IN-3 is a compound that targets PD-1/PD-L1, the IC50 value and EC50 value is 4.97nM and 2.70 μM for inhibit PD-L1 and Jurkat T cells, respectively. |
| M41724 | LSD1-IN-27 | LSD1-IN-27 is a LSD1 inhibitor (IC50: 13 nM). |
| M40594 | Genolimzumab | Genolimzumab is a PD-1 monoclonal antibody that can be used in studies related to peripheral T-cell lymphoma (PTCL). |
| M31383 | CLP-002 | CLP-002 is a low molecular weight anti-PD-L1 short peptide inhibitor, which can act by blocking the interaction between pd-1 and pd-l1, and thus can be used in tumor related studies. Sequence: WHRSYYTWNLNT |
| M31308 | IMMH-010 | IMMH-010 is a potent prodrug of the programmed cell death ligand 1 (PD-L1) inhibitor YPD-29B for studies related to oncology and neurological diseases. |
| M31307 | MAX-10181 | MAX-10181 (PD-1/PD-L1-IN-30) is a PD-1/PD-L1 binding inhibitor with an IC50 value of 0.018 μM.It can be used in studies related to solid tumors. |
| M31306 | LH1307 | LH1307 is a C2-symmetric small molecule inhibitor of PD-1:PD-L1 interactions. |
| M31305 | LH1306 | LH1306 is a small molecule inhibitor of C2 symmetric PD-1:PD-L1 interactions. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
